[L04AA27, fingolimod, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Fingolimod.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Octreotide.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Octreotide.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Octreotide.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Octreotide.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be increased when it is combined with Octreotide.]
[L01CB02, teniposide, The serum concentration of Teniposide can be increased when it is combined with Octreotide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Octreotide.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Octreotide.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin.]
[L01AC01, thiotepa, The serum concentration of Thiotepa can be increased when it is combined with Octreotide.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thiothixene.]
[S01ED01, timolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Timolol.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Octreotide.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Octreotide.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Octreotide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Octreotide.]
[A03AA05, trimebutine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Trimebutine.]
[S01ED04, metipranolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Alimemazine.]
[N03AC02, trimethadione, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Trimethadione.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triprolidine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Octreotide.]
[L01EX04, vandetanib, The serum concentration of Vandetanib can be increased when it is combined with Octreotide.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indacaterol.]
[C08DA01, verapamil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Verapamil.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Octreotide.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Octreotide.]
[L01CA03, vindesine, The serum concentration of Vindesine can be increased when it is combined with Octreotide.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Octreotide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Octreotide.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Octreotide.]
[L01ED01, crizotinib, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Octreotide.]
[L01EJ01, ruxolitinib, The serum concentration of Ruxolitinib can be increased when it is combined with Octreotide.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tolterodine.]
[C07AB03, atenolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atropine.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Octreotide.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Octreotide.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirabegron.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Octreotide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Octreotide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX05, regorafenib, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Regorafenib.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nelfinavir.]
[C08CA13, lercanidipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lercanidipine.]
[N06DA02, donepezil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Donepezil.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Octreotide.]
[H01CB05, pasireotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pasireotide.]
[L01EA05, ponatinib, The serum concentration of Ponatinib can be increased when it is combined with Octreotide.]
[C10AX12, lomitapide, The serum concentration of Lomitapide can be increased when it is combined with Octreotide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bedaquiline.]
[C04AX11, bencyclane, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.]
[C03AA01, bendroflumethiazide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Octreotide.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Octreotide.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Octreotide.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Octreotide.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.]
[C08EA02, bepridil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Octreotide.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Octreotide.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.]
[C07AB04, acebutolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Octreotide.]
[S01ED02, betaxolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Betaxolol.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Octreotide.]
[L01ED02, ceritinib, Octreotide may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Octreotide.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Octreotide.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olodaterol.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Octreotide.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Octreotide.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Octreotide.]
[L01XK01, olaparib, The serum concentration of Olaparib can be increased when it is combined with Octreotide.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirtazapine.]
[L01EF01, palbociclib, The serum concentration of Palbociclib can be increased when it is combined with Octreotide.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Octreotide.]
[C01EB17, ivabradine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Ivabradine.]
[L01XJ02, sonidegib, The serum concentration of Sonidegib can be increased when it is combined with Octreotide.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Octreotide.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CX01, trabectedin, The serum concentration of Trabectedin can be increased when it is combined with Octreotide.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Octreotide.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Octreotide.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Octreotide.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Octreotide.]
[L01XG03, ixazomib, The serum concentration of Ixazomib can be increased when it is combined with Octreotide.]
[L01ED03, alectinib, The serum concentration of Alectinib can be increased when it is combined with Octreotide.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Octreotide.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Octreotide.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Octreotide is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.]
[C08CA01, amlodipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Octreotide.]
[V10XX04, lutetium Lu 177 dotatate, The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.]
[S01ED03, levobunolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Levobunolol.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Bupivacaine.]
[C07AA19, bupranolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buserelin.]
[L01AB01, busulfan, The serum concentration of Busulfan can be increased when it is combined with Octreotide.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azatadine.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Octreotide.]
[L01EF02, ribociclib, The serum concentration of Ribociclib can be increased when it is combined with Octreotide.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pregabalin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Octreotide.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX10, midostaurin, The serum concentration of Midostaurin can be increased when it is combined with Octreotide.]
[L01ED04, brigatinib, The serum concentration of Brigatinib can be increased when it is combined with Octreotide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Delafloxacin.]
[P03AC02, bioallethrin, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bioallethrin.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be increased when it is combined with Octreotide.]
[L01EH02, neratinib, The serum concentration of Neratinib can be increased when it is combined with Octreotide.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Octreotide.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Octreotide.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bisoprolol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efavirenz.]
[C07AA17, bopindolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Bopindolol.]
[L01EL02, acalabrutinib, The serum concentration of Acalabrutinib can be increased when it is combined with Octreotide.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be decreased when it is combined with Octreotide.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Octreotide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Octreotide.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acrivastine.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Octreotide.]
[N03AF01, carbamazepine, The serum concentration of Carbamazepine can be increased when it is combined with Octreotide.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Carbinoxamine.]
[C07AG02, carvedilol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Carvedilol.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encorafenib.]
[C07AB08, celiprolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Celiprolol.]
[L01XX62, ivosidenib, The serum concentration of Ivosidenib can be increased when it is combined with Octreotide.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Octreotide.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Octreotide.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cetirizine.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Octreotide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Inotersen.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Octreotide.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Octreotide.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Octreotide.]
[S01ED05, carteolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triclabendazole.]
[L04AA42, siponimod, The serum concentration of Siponimod can be increased when it is combined with Octreotide.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Erdafitinib can be increased when it is combined with Octreotide.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ubidecarenone.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Octreotide.]
[L01EX15, pexidartinib, The serum concentration of Pexidartinib can be increased when it is combined with Octreotide.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib.]
[N07XX11, pitolisant, Octreotide may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Octreotide.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Octreotide.]
[V09IX09, edotreotide gallium ga-68, Octreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Octreotide.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Octreotide.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Octreotide.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Octreotide.]
[L01EL03, zanubrutinib, The serum concentration of Zanubrutinib can be increased when it is combined with Octreotide.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Octreotide.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Octreotide.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Octreotide.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gatifloxacin.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Octreotide.]
[C08CA16, clevidipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorcyclizine.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Octreotide.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fostemsavir.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Octreotide.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Octreotide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorprothixene.]
[N06BX18, vinpocetine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Vinpocetine.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Relugolix.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Octreotide.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07CA02, cinnarizine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinoxacin.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Octreotide.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Octreotide.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Octreotide is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Octreotide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clofazimine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Octreotide.]
[S01EA04, clonidine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Clonidine.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Octreotide.]
[A02BC08, vonoprazan, Vonoprazan can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Octreotide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Octreotide.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Cocaine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Octreotide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desflurane.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Octreotide.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Octreotide.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Octreotide.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desloratadine.]
[H01AX01, pegvisomant, The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Posaconazole.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA09, lacidipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.]
[N03AX09, lamotrigine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocabastine.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lomefloxacin.]
[C09AA03, lisinopril, The bioavailability of Lisinopril can be increased when combined with Octreotide.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Manidipine.]
[C07AA14, mepindolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Mepindolol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Adenosine.]
[C04AX01, cyclandelate, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyclizine.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Melperone.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.]
[L01AA01, cyclophosphamide, The serum concentration of Cyclophosphamide can be increased when it is combined with Octreotide.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Octreotide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Octreotide.]
[C03XA02, conivaptan, The serum concentration of Conivaptan can be increased when it is combined with Octreotide.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Octreotide.]
[C07AB12, nebivolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nebivolol.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Nefazodone.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Solifenacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Cinchocaine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Foscarnet.]
[A03AX04, pinaverium, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.]
[L01DC04, ixabepilone, The serum concentration of Ixabepilone can be increased when it is combined with Octreotide.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be increased when it is combined with Octreotide.]
[C08CA03, isradipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Isradipine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Octreotide.]
[C01AA05, digoxin, The serum concentration of Digoxin can be decreased when it is combined with Octreotide.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Octreotide.]
[N02CA01, dihydroergotamine, The serum concentration of Dihydroergotamine can be increased when it is combined with Octreotide.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Treprostinil.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Pramocaine.]
[C08DB01, diltiazem, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dimenhydrinate.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Diphenhydramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Octreotide.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Octreotide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disulfiram.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rosoxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Octreotide.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Octreotide.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Octreotide.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Octreotide.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxylamine.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Droperidol.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sultopride.]
[C07AB13, talinolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temafloxacin.]
[G04BD05, terodiline, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Terodiline.]
[C07AA16, tertatolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Tertatolol.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Octreotide.]
[M01AG02, tolfenamic acid, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Tolfenamic acid.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atomoxetine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Toremifene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Enoxacin.]
[L01CA04, vinorelbine, The serum concentration of Vinorelbine can be increased when it is combined with Octreotide.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Venlafaxine.]
[C08CA12, mepirodipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Barnidipine.]
[N03AX15, zonisamide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Octreotide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Octreotide.]
[C02AC02, guanfacine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moricizine.]
[N02CA02, ergotamine, The serum concentration of Ergotamine can be increased when it is combined with Octreotide.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Erythromycin.]
[A02BC02, pantoprazole, Pantoprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Octreotide.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Octreotide.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibutilide.]
[N03AD01, ethosuximide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Ethosuximide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Octreotide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Astemizole can be increased when it is combined with Octreotide.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terfenadine.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Octreotide.]
[C08CA02, felodipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Felodipine.]
[C08EA01, fendiline, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Fendiline.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Octreotide.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salbutamol.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluconazole.]
[N07CA03, flunarizine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Flunarizine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Octreotide.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flupentixol.]
[N05AG01, fluspirilene, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Fluspirilene.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Octreotide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amisulpride.]
[N06DA04, galantamine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Galantamine.]
[C08DA02, gallopamil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Octreotide.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Octreotide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.]
[N03AD03, methsuximide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Methsuximide.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Octreotide.]
[N01AH02, alfentanil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Octreotide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Octreotide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Octreotide.]
[N05CM18, dexmedetomidine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Dexmedetomidine.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Octreotide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Octreotide.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be increased when it is combined with Octreotide.]
[C07AB09, esmolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Esmolol.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Octreotide.]
[L01CE02, irinotecan, The serum concentration of Irinotecan can be increased when it is combined with Octreotide.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Losartan.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Octreotide.]
[C08CA10, nilvadipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nilvadipine.]
[M02AA26, nimesulide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydrochlorothiazide.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.]
[L01AA06, ifosfamide, The serum concentration of Ifosfamide can be increased when it is combined with Octreotide.]
[N01AH03, sufentanil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Sufentanil.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.]
[L01CD01, paclitaxel, The serum concentration of Paclitaxel can be increased when it is combined with Octreotide.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terlipressin.]
[M03BX02, tizanidine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Tizanidine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Octreotide.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buclizine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anagrelide.]
[C07AA01, alprenolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Alprenolol.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isoflurane.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olanzapine.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mizolastine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Lipoic acid.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nalidixic acid.]
[C07AG01, labetalol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amantadine.]
[N03AX18, lacosamide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lacosamide.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Octreotide.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Lidocaine.]
[C08EX01, lidoflazine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lidoflazine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Octreotide.]
[A07DA03, loperamide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Loperamide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Octreotide.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Octreotide.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Octreotide.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The serum concentration of Nilotinib can be increased when it is combined with Octreotide.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be decreased when it is combined with Octreotide.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mefloquine.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Octreotide.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dolasetron.]
[H01CB03, lanreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lanreotide.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methadone.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Octreotide.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methotrimeprazine.]
[C02AB01, methyldopa, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Methyldopa.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Octreotide.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Octreotide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.]
[C07AB02, metoprolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metronidazole.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Octreotide.]
[C01CA17, midodrine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Midodrine.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Octreotide.]
[C01BD01, amiodarone, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amitriptyline.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Octreotide.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amodiaquine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Octreotide.]
[C07AA12, nadolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nadolol.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.]
[L01CD02, docetaxel, The serum concentration of Docetaxel can be increased when it is combined with Octreotide.]
[N01AH06, remifentanil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Remifentanil.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Octreotide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Octreotide.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Desvenlafaxine.]
[C08CA04, nicardipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nicardipine.]
[C08CA05, nifedipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nifedipine.]
[C08CA06, nimodipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nimodipine.]
[C08CA07, nisoldipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nisoldipine.]
[C08CA08, nitrendipine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nitrendipine.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Octreotide.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Norfloxacin.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Octreotide.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Octreotide.]
[G02CA02, nylidrin, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nylidrin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pipemidic acid.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ofloxacin.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Oxprenolol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Asenapine.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Octreotide.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pefloxacin.]
[C07AA23, penbutolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Penbutolol.]
[N05AG03, penfluridol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Penfluridol.]
[C08EX02, perhexiline, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Perhexiline.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pheniramine.]
[B01AA04, phenprocoumon, The serum concentration of Phenprocoumon can be increased when it is combined with Octreotide.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.]
[L02BB03, bicalutamide, The serum concentration of Bicalutamide can be increased when it is combined with Octreotide.]
[C08CX01, mibefradil, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Mibefradil.]
[N05AG02, pimozide, The serum concentration of Pimozide can be increased when it is combined with Octreotide.]
[C07AA03, pindolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Octreotide.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Grepafloxacin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Octreotide.]
[C07AB01, practolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prajmaline.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Antazoline.]
[C01DX02, prenylamine, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Primaquine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Procaine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Octreotide.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promethazine.]
[C01BC03, propafenone, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Propafenone.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Octreotide.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propofol.]
[C07AA05, propranolol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Propranolol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Protriptyline.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Octreotide.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mepyramine.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Octreotide.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Octreotide.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Roxithromycin.]
[C07AA07, sotalol, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Sotalol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Octreotide.]
